Prazosin
- Generic Name
- Prazosin
- Brand Names
- Minipress, Minizide
- Drug Type
- Small Molecule
- Chemical Formula
- C19H21N5O4
- CAS Number
- 19216-56-9
- Unique Ingredient Identifier
- XM03YJ541D
- Background
Prazosin is a drug used to treat hypertension. Prazosin is marketed by Pfizer and was initially approved by the FDA in 1988. It belongs to the class of drugs known as alpha-1 antagonists.
Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTSD) and associated nightmares.
- Indication
This drug is indicated for the treatment of hypertension (high blood pressure). Prazosin can be given alone or given with other blood pressure-lowering drugs, including diuretics or beta-adrenergic blocking agents .
...
- Associated Conditions
- Agitation, Benign Prostatic Hyperplasia (BPH), Hypertension, Raynaud's Phenomenon, Disturbed sleep/nightmares
- Associated Therapies
- -
Brain Blood Vessel Responses to Changes in Blood Flow
- Conditions
- Interventions
- First Posted Date
- 2024-10-07
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 36
- Registration Number
- NCT06629090
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
Brain Blood Vessel Responses to Changes in Blood Flow
- Conditions
- Interventions
- First Posted Date
- 2024-10-07
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 36
- Registration Number
- NCT06629077
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
- Conditions
- Interventions
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2024-01-23
- Target Recruit Count
- 34
- Registration Number
- NCT05189977
- Locations
- 🇺🇸
For additional information regarding sites (California, Texas, New Jersey, Minnesota), Princeton, New Jersey, United States
Prazosin for Alcohol Use Disorder With Withdrawal Symptoms
- Conditions
- Interventions
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Yale University
- Target Recruit Count
- 150
- Registration Number
- NCT04793685
- Locations
- 🇺🇸
The Yale Stress Center: Yale University, New Haven, Connecticut, United States
Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 5
- Registration Number
- NCT04365257
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
Administration of Prazosin to Prevent PTSD in Adult Women After Sexual Assault
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 40
- Registration Number
- NCT03997864
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
Prazosin Use in Adults With Anxiety Disorders
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- University of Manitoba
- Target Recruit Count
- 20
- Registration Number
- NCT03894345
- Locations
- 🇨🇦
University of Manitoba - PsycHealth - Mood and Anxiety Disorders Clinic, Winnipeg, Manitoba, Canada
Prazosin for Agitation in Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
- Target Recruit Count
- 35
- Registration Number
- NCT03710642
- Locations
- 🇺🇸
Northern Light/Acadia Hospital Eastern Maine Medical Center, Bangor, Maine, United States
🇺🇸SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸VAMC: James J Peters, Bronx, New York, United States
Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 70
- Registration Number
- NCT03539614
- Locations
- 🇺🇸
VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States
Effects of Prazosin on the Attention-Enhancing Effects of Nicotine
- Conditions
- Interventions
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT03416569
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.